Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference

Adrianna Vlachos(Albert Einstein College of Medicine), Sarah E. Ball(St George's Hospital), Niklas Dahl(Uppsala University), Blanche P. Alter(National Cancer Institute), Sujit Sheth(Columbia University), Ugo Ramenghi(University of Turin), Joerg J Meerpohl(Zentrum für Kinderheilkunde), Stefan Karlsson(Lund University), Johnson M. Liu(Albert Einstein College of Medicine), Thierry Leblanc(Hôpital Saint-Louis), Carole Paley(Novartis (United States)), Elizabeth M. Kang(National Institutes of Health), Eva Judmann Leder(Feinstein Institute for Medical Research), Eva Atsidaftos(Albert Einstein College of Medicine), Akiko Shimamura(Boston Children's Museum), Monica Bessler(Washington University in St. Louis), Bertil Glader(Palo Alto University), Jeffrey M. Lipton(Albert Einstein College of Medicine), on behalf of the participants of the Sixth Annual Daniella Maria Arturi International Consensus Conference
British Journal of Haematology
July 30, 2008
Cited by 471Open Access
Full Text

Abstract

Diamond Blackfan anaemia (DBA) is a rare, genetically and clinically heterogeneous, inherited red cell aplasia. Classical DBA affects about seven per million live births and presents during the first year of life. However, as mutated genes have been discovered in DBA, non-classical cases with less distinct phenotypes are being described in adults as well as children. In caring for these patients it is often difficult to have a clear understanding of the treatment options and their outcomes because of the lack of complete information on the natural history of the disease. The purpose of this document is to review the criteria for diagnosis, evaluate the available treatment options, including corticosteroid and transfusion therapies and stem cell transplantation, and propose a plan for optimizing patient care. Congenital anomalies, mode of inheritance, cancer predisposition, and pregnancy in DBA are also reviewed. Evidence-based conclusions will be made when possible; however, as in many rare diseases, the data are often anecdotal and the recommendations are based upon the best judgment of experienced clinicians. The recommendations regarding the diagnosis and management described in this report are the result of deliberations and discussions at an international consensus conference.


Related Papers